Search Within

Katherine S Panageas

  1. "Molecular Pharmacology and Chemistry Program Faculty"
Formats
  1. Journal Article (18)
  2. Meeting Abstract (8)
Groups
  1. Biostatistics Service (26)
  2. Epidemiology and Biostatistics (26)
  3. Molecular Pharmacology and Chemistry Program Faculty (26)
  4. Population Sciences Research Program (26)
  5. Sloan Kettering Institute Faculty (26)
  6. GSK Faculty (23)

More Groups

People
  1. David Scheinberg (13)
  2. Steven Larson (8)
  3. Joseph Jurcic (7)
  4. David Solit (6)
  5. Neal Rosen (6)
  6. Paul Chapman (6)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2021 (1)
  4. 2017 (2)
  5. 2016 (1)
  6. 2015 (1)

More Years

Publications
  1. Clinical Cancer Research (5)
  2. Journal of Clinical Oncology (5)
  3. Journal of Nuclear Medicine (4)
  4. Cancer Research (2)
  5. Blood (1)
  6. Bone Marrow Transplantation (1)

More Publications

Publishers
  1. American Association for Cancer Research (7)
  2. American Society of Clinical Oncology (6)
  3. Society of Nuclear Medicine (4)
  4. Oxford University Press (2)
  5. American Society of Hematology (1)
  6. National Academy of Sciences (1)

More Publishers

Results (26)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neopeptide diversity and similarity to the unmutated immunopeptidome is associated with response to immune checkpoint blockade therapy
    Meeting Abstract

    Klatt, M.; Molvi, Z.; Panageas, K.; Wells, D.; Hellmann, M.; Merghoub, T.; Wolchok, J.; O'Reilly, R.; Keller, U.; Scheinberg, D.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Long-term survival from a phase 1 doseescalation trial using convection-enhanced delivery (CED) of radioimmunotherapeutic (124)I-omburtamab for treatment of diffuse intrinsic pontine glioma (DIPG)
    Meeting Abstract

    Souweidane, M. M.; Kramer, K.; Pandit-Tasker, N.; Haque, S.; Zanzonico, P.; Carrasquillo, J.; Lyashchenko, S. K.; Thakur, S. B.; Khakoo, Y.; Dunkel, I. J.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Therapeutic implications of detecting MAPK-activating alterations in cutaneous and unknown primary melanomas
    Journal Article

    Shoushtari, A. N.; Chatila, W. K.; Arora, A.; Sanchez-Vega, F.; Kantheti, H. S.; Rojas Zamalloa, J. A.; Krieger, P.; Callahan, M. K.; Betof Warner, A.; Postow, M. A.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • PTEN loss-of-function alterations are associated with intrinsic resistance to BRAF inhibitors in metastatic melanoma
    Journal Article

    Catalanotti, F.; Cheng, D. T.; Shoushtari, A. N.; Johnson, D. B.; Panageas, K. S.; Momtaz, P.; Higham, C.; Won, H. H.; Harding, J. J.; Merghoub, T.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma
    Journal Article

    Zauderer, M. G.; Tsao, A. S.; Dao, T.; Panageas, K.; Lai, W. V.; Rimner, A.; Rusch, V. W.; Adusumilli, P. S.; Ginsberg, M. S.; Gomez, D.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Randomized phase II study of adjuvant WT1 vaccine (SLS-001) for malignant pleural mesothelioma (MPM) after multimodality therapy
    Meeting Abstract

    Zauderer, M. G.; Dao, T.; Rusch, V. W.; Ginsberg, M. S.; Tsao, A. S.; Panageas, K.; Stergiou, A. M.; Scheinberg, D. A.; Krug, L. M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A retrospective evaluation of vemurafenib as treatment for BRAF-mutant melanoma brain metastases
    Journal Article

    Harding, J. J.; Catalanotti, F.; Munhoz, R. R.; Cheng, D. T.; Yaqubie, A.; Kelly, N.; McDermott, G. C.; Kersellius, R.; Merghoub, T.; Lacouture, M. E.; more...
    The Oncologist (2015)

    Fulltext@MSK | Save
  • Phase II trial of MEK inhibitor selumetinib (AZD6244) in patients with BRAFV600E/K- or NRAS-mutated melanoma
    Meeting Abstract

    Catalanotti, F.; Solit, D. B.; Pulitzer, M. P.; Berger, M. F.; Scott, S. N.; Iyriboz, T.; Lacouture, M. E.; Panageas, K. S.; Wolchok, J. D.; Carvajal, R. D.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Cure models for the analysis of time-to-event data in cancer studies
    Journal Article

    Jia, X.; Sima, C. S.; Brennan, M. F.; Panageas, K. S.
    Journal of Surgical Oncology (2013)

    Fulltext@MSK | Save
  • Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma
    Journal Article

    Catalanotti, F.; Solit, D. B.; Pulitzer, M. P.; Berger, M. F.; Scott, S. N.; Iyriboz, T.; Lacouture, M. E.; Panageas, K. S.; Wolchok, J. D.; Carvajal, R. D.; more...
    Clinical Cancer Research (2013)

    Fulltext@MSK | Save